NCT05961527View on ClinicalTrials.gov

Group MDMA-therapy for Veterans With PTSD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
PTSD
Interventions
DRUG

MDMA

Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose

BEHAVIORAL

Group Therapy

Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy

Trial Locations (1)

98661

Portland-Vancouver VA, Vancouver

All Listed Sponsors
collaborator

Steven & Alexandra Cohen Foundation

OTHER

lead

Portland VA Research Foundation, Inc

OTHER

NCT05961527 - Group MDMA-therapy for Veterans With PTSD | Biotech Hunter | Biotech Hunter